Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – Haematological malignancies

5925 - Obstetric and maternal outcome of 134 patients with Hodgkin lymphoma diagnosed during pregnancy: results from the INCIP registry


30 Sep 2019


Poster Discussion – Haematological malignancies


Frederic Amant


Annals of Oncology (2019) 30 (suppl_5): v435-v448. 10.1093/annonc/mdz251


F. Amant1, C. Maggen2, D. Dierickx3, E. Lugtenburg4, A. Laenen5, E. Cardonick6, R.G. Shmakov7, M. Bellido Casado8, A.C. Garcia9, M. Gziri10, M. Halaska11, P. Ottevanger12, K. Van Calsteren13, A. L'Hauglin6, E. Polushkina7, L. Van Dam4, P. Vandenberghe3, S.H. Woei-A-Jin14

Author affiliations

  • 1 Department Of Gynecologic Oncology, Antoni Van Leeuwenhoek Hospital – The Netherlands Cancer Institute, 1066CX - Amsterdam/NL
  • 2 Obstetrics And Gynecology, University Hospitals Leuven and Department of Oncology, KU Leuven, 3000 - Leuven/BE
  • 3 Department Of Hematology, University Hospitals Leuven and Department of Oncology, KU Leuven, 3000 - Leuven/BE
  • 4 Hematology, Erasmus University Medical Center, 3015 CE - Rotterdam/NL
  • 5 Biostatistics And Statistical Bioinformatics Center, KU Leuven, 3000 - Leuven/BE
  • 6 Obstetrics And Gynecology, Cooper University Hospital, Philadelphia/US
  • 7 Academician V.i.kulakov Of The Ministry Of Healthcare Of Russian Federation, National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow/RU
  • 8 Department Of Hematology, University Medical Centre Groningen, Groningen/NL
  • 9 Oncology, Hospital Regional de Alta Especialidad de Ixtapaluca (HRAEI), Mexico City/MX
  • 10 Obstetrics, Cliniques Universitaires St Luc, Brussels/BE
  • 11 Obstetrics And Gynecology, 3rd Medical Faculty Charles University and Faculty Hospital Kralovske Vinohrady, Prague/CZ
  • 12 Internal Medicine, Radboud UMC Nijmegen, Nijmegen/NL
  • 13 Obstetrics And Gynecology, University Hospitals Leuven and Department of Development and Regeneration, KU Leuven, Leuven/BE
  • 14 Medical Oncology, University Hospitals Leuven and Department of Oncology, KU Leuven, 3000 - Leuven/BE


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5925


The purpose of this study was to assess obstetric and maternal outcome of pregnant patients with diagnosis of Hodgkin lymphoma (HL) registered by the International Network on Cancer, Infertility and Pregnancy (INCIP) to guide physicians in clinical management.


Clinical data of pregnant patients diagnosed with HL between 1969 and 2018 were collected from the INCIP registry. For survival analysis of classical HL treated with an ABVD-based regimen, non-pregnant controls were selected based on stage and prognostic score at diagnosis.


The median gestational age at diagnosis of 134 eligible patients was 20 weeks (range: 3 – 37). Antenatal chemotherapy was initiated in 53.7% of patients. Ten (7.5%) early pregnancies were terminated. One foetus deceased in the third trimester after three cycles of chemotherapy. In total, 120 (89.6%) pregnancies ended in a live birth. Preterm delivery was observed in 47 (40.1%) singleton pregnancies. Birth weight percentiles were lower in children prenatally exposed to oncological treatment and 17.9% were small for gestational age at birth. Four children (3.5%) had major congenital malformations. Five-year progression-free survival (PFS) for HL during pregnancy was 82.5% and 90.9% for early (n = 62) and advanced stage (n = 15). Five-year overall survival (OS) was 97.3% and 100%, respectively. Although not significant, patients with early stage HL appeared to have inferior PFS compared with matched non-pregnant controls (n = 62), more clearly seen in the subgroup that initiated chemotherapy during pregnancy (n = 45). OS was comparable between both groups, supporting the effectiveness of salvage therapy. For advanced stage HL survival was similar to controls, albeit small numbers.


Although further prospective research on the efficacy of chemotherapy during pregnancy is necessary, survival of patients diagnosed with early stage HL during pregnancy appears not to be statistically different from matched non-pregnant controls, Awareness of complications as preterm delivery and low birth weight is important in this population.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

The authors.


European Union’s Horizon 2020 Research and Innovation Program under grant agreement No 647047 Research Foundation-Flanders (FWO., grant no G070514N) and ESGO (European Society of Gynaecological Oncology) Charles University Research Project Progres Q28 and Q34 and by grant MH CZ - DRO ("Kralovske Vinohrady University Hospital - FNKV, 00064173").


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.